The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.

PFS result in DREAMM-3 Median PFS in DREAMM-3 was numerically longer at 11.2 months for belantamab mafodotin compared to 7.0 months for pomalidomide and dexamethasone; however, the overall difference between arms in the risk of disease progression or death did not reach statistical significance at the primary analysis (hazard ratio, 1.03; 95% CI, 0.72–1.47; P = 0.56) [ 14 ].

also in 111,027 other papers

At the time of the interim PFS analysis for DREAMM-8, the belantamab mafodotin regimen demonstrated a positive trend for improved OS, with follow-up ongoing for the next preplanned OS analysis.

also in 11,005 other papers